Answers are grounded in this paper and cite their sources.
BACKGROUND: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by immune dysregulation, autoantibody production, systemic inflammation, and frequent hematological abnormalities. Interleukin-39 (IL-39), a proposed member of the IL-12 cytokine family composed of IL-23p19 and Epstein–Barr virus-induced gene 3 (EBI3) subunits, has been implicated in inflammatory immune responses, but its relationship with SLE-associated genetic variation remains incompletely characterized. MATERIALS AND METHODS: This case–control study included 100 women: 50 patients with SLE and 50 age-matched healthy controls. Serum IL-39 was measured by enzyme-linked immunosorbent assay, and white blood cell (WBC) count, hemoglobin (Hb), and erythrocyte sedimentation rate (ESR) were assessed using standard laboratory procedures. The IL23A rs11171806 and EBI3 rs4740 polymorphisms were investigated using polymerase chain reaction-based genotyping with allele-specific amplification and agarose gel electrophoresis. Disease activity was assessed using the Systemic Lupus Erythematosus Disease Activity Index. RESULTS: Patients with SLE had higher serum IL-39 concentrations and ESR and lower WBC counts and Hb levels than controls. Serum IL-39 increased across the reported SLE activity categories. The distributions of IL23A rs11171806 and EBI3 rs4740 genotypes differed between patients and controls in the available genotype dataset, suggesting associations between these variants and SLE susceptibility. CONCLUSION: Serum IL-39, hematological alterations, and IL23A/EBI3 genetic variation were associated with SLE in this study. These findings are exploratory and require confirmation in larger, independent, and ethnically diverse cohorts.
No takes yet. Share an insight, caveat, or question.
Mohsen et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: